Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624540 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CA12CA9MAPTKDM4E | |
| Ethylene SCHEMBL9096059 | 0.96 | ALDH1A1 (0.70) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL20876339 | 0.85 | ALDH1A1 (0.71) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL4681571 | 0.85 | ALDH1A1 (0.71) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL10671092 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL14282655 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL8940040 | 0.83 | CA12 (0.73) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL1274905 | 0.82 | ALDH1A1 (1.00) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL29744481 | 0.81 | CA12 (1.00) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL11148327 | 0.81 | CA12 (0.70) | ALDH1A1CA12CA9MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441812-B2 | Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules | HOFFMANN-LA ROCHE INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3738609-B1 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER | HOFFMANN LA ROCHE (CH) | 2025-06-18 | — | — | EP | disclosed |
| US-20250101135-A1 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250090611-A1 | T CELL DIFFERENTIATION-REGULATING AGENT AND COMPOSITION | KJ BIO CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| CN-118955409-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4431105-A1 | T-CELL DIFFERENTIATION REGULATING AGENT AND COMPOSITION | KJ Bio Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-112867539-B | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4308564-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-20230372403-A1 | IMMUNOENGINEERING BIOMATERIALS FOR TREATMENT OF GRAFT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-23 | — | — | US | disclosed |
| EP-4225336-A1 | IMMUNOENGINEERING BIOMATERIALS FOR TREATMENT OF GRAFT REJECTION | The Regents of The University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023085351-A1 | T-CELL DIFFERENTIATION REGULATING AGENT AND COMPOSITION | 株式会社デンソー | 2023-05-19 | — | — | WO | disclosed |
| WO-2022197789-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220259327-A1 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER | HOFFMANN-LA ROCHE INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259326-A1 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER | HOFFMANN-LA ROCHE INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114746149-A | 1,2, 4-oxadiazole derivatives as liver X receptor agonists | 诺华股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11306154-B2 | Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer | HOFFMANN-LA ROCHE INC. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2022076673-A1 | IMMUNOENGINEERING BIOMATERIALS FOR TREATMENT OF GRAFT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11267903-B2 | Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer | HOFMANN-LA ROCHE INC. (US) | 2022-03-08 | — | — | US | disclosed |